{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:55:05Z","timestamp":1759366505719,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.revmed.2022.09.003","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T02:12:38Z","timestamp":1662603158000},"page":"634-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chez les sujets hospitalis\u00e9s pour COVID-19, est-ce que le baricitinib diminue la mortalit\u00e9 \u00e0 28 jours comparativement aux traitements standards tout en \u00e9tant s\u00e9curitaire\u00a0?"],"prefix":"10.1016","volume":"43","author":[{"given":"L.","family":"Lanthier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-\u00c9.","family":"Plourde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cauchon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2022.09.003_bib0060","unstructured":"https:\/\/gisanddata.maps.arcgis.com\/apps\/opsdashboard\/index.html#\/bda7594740fd40299423467b48e9ecf6."},{"issue":"23","key":"10.1016\/j.revmed.2022.09.003_bib0065","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.revmed.2022.09.003_bib0070","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19\u00a0severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.revmed.2022.09.003_bib0075","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"issue":"10285","key":"10.1016\/j.revmed.2022.09.003_bib0080","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2022.09.003_bib0085","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2022.09.003_bib0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19\u00a0on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2022.09.003_bib0095","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3\u00a0trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10349","key":"10.1016\/j.revmed.2022.09.003_bib0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","author":"Abani","year":"2022","journal-title":"Lancet"},{"author":"National Institutes of Health","key":"10.1016\/j.revmed.2022.09.003_bib0105"},{"key":"10.1016\/j.revmed.2022.09.003_bib0055","unstructured":"WHO. Therapeutics and COVID-19: Living guideline. V9.2. 14\u00a0Jan. https:\/\/app.magicapp.org\/#\/guideline\/nBkO1E\/rec\/E5AOaN (accessed Feb 25, 2022)."}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322006373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322006373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:45:30Z","timestamp":1759337130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866322006373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0248866322006373"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2022.09.003","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chez les sujets hospitalis\u00e9s pour COVID-19, est-ce que le baricitinib diminue la mortalit\u00e9 \u00e0 28jours comparativement aux traitements standards tout en \u00e9tant s\u00e9curitaire\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2022.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}